Suggested remit: To appraise the clinical and cost effectiveness of mirdametinib within its marketing authorisation for for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6618
Provisional Schedule
- Expected publication:
- 03 September 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email tateam3@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- SpringWorks Therapeutics
- Others
- Department of Health and Social Care
- Guy’s and St Thomas’ NHS Foundation Trust
- Manchester University NHS Foundation Trust
- NHS England
- Patient carer groups
- Brain and Spine Foundation
- Brain Charity
- Childhood Tumour Trust
- Genetic Alliance UK
- Nerve Tumour UK
- Neurological Alliance
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Anaesthetists
- Association of British Neurologists
- Association of Cancer Physicians
- Association of Genetic Nurses & Counsellors
- Association of Surgeons of Great
- Britain and Ireland
- British Association of Paediatric Surgeons
- British Geriatrics Society
- British Neuro-Oncology Society
- British Neuropathological Society
- British Paediatric Neurology Association
- British Pharmacological Society
- British Society for Gene and Cell Therapy
- British Society for Genetic Medicine
- Institute of Neurology
- Primary Care and Community Neurology Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Assessment group
- Brain Research UK
- Children’s & Young People’s Cancer Association (Children’s Cancer & Leukaemia Group)
- Cochrane Cystic Fibrosis & Genetic
- Disorders Group
- Genomics England
- MRC Clinical Trials Unit
- National Hospital for Neurology and Neurosurgery
- National Institute for Health Research
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Alexion (selumetinib)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- Neurological Alliance of Scotland
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Wales Neurological Alliance
- Welsh Government
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 February 2026 | Invitation to participate |
| 22 October 2025 - 19 November 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 22 October 2025 | In progress. Scoping commenced. |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 28 May 2025 | Topic prioritisation |
For further information on our processes and methods, please see our CHTE processes and methods manual